- Management of recurrent gastrointestinal bleeding in von Willebrand disease patients, often due to angiodysplasia, lacks targeted therapies.
- Researchers investigated VWF-deficient human endothelial cells and VWF-deficient mice to understand angiodysplasia pathogenesis.
- Loss of VWF increased Angiopoietin-2 expression in endothelial cells and led to abnormal vascular remodeling in a 3D model.
- The study concludes that von Willebrand factor regulates the Angiopoietin/Tie2 balance, influencing gut vascular integrity.
- Inhibiting Angiopoietin-2 reduced abnormal sprouting and normalized vascular remodeling, suggesting a potential therapeutic target for VWD-associated angiodysplasia.
Unraveling Gut Angiodysplasia in Von Willebrand Disease
For patients with von Willebrand disease (VWD), recurrent gastrointestinal bleeding from angiodysplasia, a type of vascular malformation, remains a significant and difficult-to-manage clinical problem [1]. While von Willebrand factor (VWF) is known for its primary role in hemostasis, emerging evidence indicates it also helps regulate the formation of new blood vessels (angiogenesis) and maintain vascular integrity [2, 3]. The link may involve angiopoietin-2, an angiogenesis regulator stored in endothelial cells and influenced by VWF [4]. However, the precise mechanism by which VWF deficiency leads to the abnormal gut vasculature seen in angiodysplasia has been unclear, hindering the development of targeted therapies [5, 6, 7, 8].
VWF's Role in Angiogenesis and Angiopoietin-2 Regulation
Beyond its hemostatic function, VWF's influence on the health of the endothelium is a key area of investigation. Prior work established that VWF controls the storage of the angiogenesis regulator angiopoietin-2 (Angpt-2) in endothelial cells, suggesting a direct link between the clotting factor and a potent modulator of vascular growth. This was a critical observation, as Angpt-2 is known to destabilize vessel walls to permit remodeling. Despite this, a direct causal link was missing; no direct evidence of the role of Angpt-2 in VWF-dependent angiogenesis was previously available. This study was designed to bridge that knowledge gap by investigating if and how Angpt-2 dysregulation directly drives the pathological vessel growth associated with VWF deficiency.
Molecular Mechanism: The Angpt-2 Feedback Loop
To define the molecular pathway at the heart of this process, researchers used two complementary in vitro models. They first employed VWF-deficient human umbilical vein endothelial cells (HUVEC), a standard laboratory cell line that allows for controlled study of endothelial biology. To ensure clinical relevance, they also studied endothelial colony-forming cells (ECFCs), which are progenitor cells isolated directly from the blood of patients with severe VWD. In both models, the findings were consistent: the loss of VWF resulted in increased Angpt-2 expression. The investigation revealed this was not a simple consequence but was driven by a positive feedback loop identified as Angpt-2-Tie-2-Akt-FOXO1-Angpt-2. In this self-amplifying intracellular signaling cascade, the initial overabundance of Angpt-2 triggers a pathway that leads to even greater Angpt-2 production, creating a vicious cycle that promotes a pro-angiogenic state.
In Vivo Validation: Insights from VWF-Deficient Mice
To determine if these cellular findings translate to a whole organism, the study team examined the gut vasculature of VWF-deficient mice. The analysis revealed a critical imbalance in the gut tissue: Angpt-2 expression was increased, whereas Angpt-1 expression was decreased. This shift is significant because Angpt-1 is typically associated with vascular stability, while Angpt-2 promotes instability and angiogenesis. The data suggest VWF is essential for maintaining the proper Angpt-1/Angpt-2 balance required for a healthy gut vasculature. Correspondingly, physical examination of the jejunum in these mice showed that the intestinal vasculature appeared abnormal, with hypersprouting and lumen formation defects. These pathologies closely mimic the appearance of angiodysplasia in humans, establishing VWF-deficient mice as a relevant animal model to study the condition.
Modeling Angiodysplasia: In Vitro and 3D Systems
To further probe the cellular behaviors driving these malformations, the researchers utilized a fibrin bead assay, a technique for visualizing new vessel growth in a dish. This experiment confirmed that VWF-deficient endothelial cells exhibit increased sprouting, providing a cellular basis for the hypersprouting seen in the animal model. The investigation then advanced to a more complex 3-dimensional microfluidic model of angiogenesis, a system that better recapitulates the physiological environment of a blood vessel network. When ECFCs from patients with severe VWD were cultured in this system, they displayed defective remodeling and abnormal lumen formation. These abnormalities were strikingly similar to the defects observed in the gut of VWF-deficient mice, directly linking the cellular-level dysfunction in patient-derived cells to the tissue-level pathology seen in vivo.
Targeting Angiopoietin-2: A Potential Therapeutic Avenue
The study's findings culminate in a potential mechanism-based treatment strategy. Having established Angpt-2 as the key driver of pathology, the researchers tested whether blocking it could reverse the defects. The results were compelling: in the laboratory cell line, inhibition of Angpt-2 reduced sprouting in VWF-deficient HUVEC. More importantly for clinical translation, in the cells derived from patients with severe VWD, Angpt-2 inhibition normalized vascular remodeling in VWD-ECFCs. This restoration of normal vessel architecture in patient cells suggests that Angpt-2 inhibitors may be an effective therapy for the underlying cause of recurrent GI bleeding in VWD. Such an approach would target the genesis of angiodysplasia itself, offering a potential improvement over current strategies that primarily manage bleeding events after they occur.
References
1. Constantinescu-Bercu A, Smith KE, Wong SY, et al. Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia.. Blood. 2026. doi:10.1182/blood.2025031558
2. Randi AM, Smith KE, Castaman G. von Willebrand factor regulation of blood vessel formation. Blood. 2018. doi:10.1182/blood-2018-01-769018
3. Randi A. Von Willebrand Factor in Angiogenesis and Angiodysplasia. Blood. 2018. doi:10.1182/BLOOD-2018-99-109556
4. Groeneveld DJ, Sanders YV, Adelmeijer J, et al. Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.. Thrombosis and haemostasis. 2018. doi:10.1160/TH17-06-0397
5. Nowak‐Sliwinska P, Alitalo K, Allen E, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018. doi:10.1007/s10456-018-9613-x
6. Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound Healing: A Cellular Perspective. Physiological Reviews. 2018. doi:10.1152/physrev.00067.2017
7. Faruque LI, Lin M, Battistella M, et al. Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer. PLoS ONE. 2014. doi:10.1371/journal.pone.0101145
8. Guetz GD, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. British Journal of Cancer. 2006. doi:10.1038/sj.bjc.6603176